Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NBP with free AI briefings, catalyst countdowns, and dilution alerts.

NBP · NovaBridge Biosciences

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$190.8M Cash on Hand
50.1mo Cash Runway
Follow NBP by email Get an email when NBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NBP, unsubscribe in one click. Privacy

📣 What NBP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NBP holds $190.8M in cash and short-term investments and burns about $11.4M/quarter from operations, an estimated runway of 50.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NBP files for a raise →

👥 Who Owns NBP

Insiders 12.2% Other 5%+ holders 16% Institutions (60 holders) 30.7% Public and other holders 41.1%
HolderTypeShares% of sharesAs of
Everest Medicines Limited 5%+ holder (13D) 42,524,716 16.02% 2025-08-05
Wei Fu
Director · +2.10M options
Insider 30,499,699 11.49% 2026-03-18
Xiaofan Neo Zhang
Chief Investment Officer
Insider 874,000 0.33% 2026-03-18
Cong Claire Xu
EVP, Clinical Development · +28,558 options
Insider 304,201 0.11% 2026-08-30
Sean Wuxiong Cao
Chief Bus. Development Officer · +317,250 options
Insider 266,467 0.10% 2026-09-09
Mark Arnold Hagler
Chief Commercial Officer · +949,050 options
Insider 230,000 0.09% 2026-04-24
Phillip Andrew Dennis
Chief Medical Officer · +72,120 options
Insider 173,427 0.07% 2026-09-17
Xi-Yong Fu
Chief Executive Officer and Director Exh
Insider 59,823 0.02% 2026-03-18
Robert A. Lenz
Director · +14,974 options
Insider 17,218 0.01% 2026-08-22
Ian Ying Woo
Director · +11,540 options
Insider 13,271 0.01% 2026-10-15
Joanna Xuqiong Wu
Officer
Insider 5,750 0.00% 2026-03-18

Share count 265,377,891 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NBP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.